Structure-based approaches against COVID-19

被引:1
|
作者
Huang, Ta-Chou [1 ,2 ]
Liang, Kung-Hao [1 ,3 ,4 ]
Chang, Tai-Jay [1 ,5 ,6 ]
Hung, Kai-Feng [1 ]
Wang, Mong-Lien [1 ,3 ]
Cheng, Yen-Fu [1 ]
Liao, Yi-Ting [1 ]
Yang, De-Ming [1 ,2 ,7 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med Res, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Inst Biophoton, Sch Biomed Sci & Engn, Taipei, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Food Safety & Hlth Risk Assessment, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Inst Biomed Informat, Sch Med, Taipei, Taiwan
[5] Taipei Vet Gen Hosp, Dept Med Res, Basic Res Div, Lab Genome Res, Taipei, Taiwan
[6] Natl Yang Ming Chiao Tung Univ, Sch Biomed Sci & Engn, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Med Res, Microscopy Serv Lab, Basic Res Div, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan
关键词
COVID-19; Molecular dynamics simulation; SARS-CoV-2; BIOLOGY;
D O I
10.1097/JCMA.0000000000001043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic has had a major impact on human life. This review highlights the versatile roles of both classical and modern structure-based approaches for COVID-19. X-ray crystallography, nuclear magnetic resonance spectroscopy, and cryogenic electron microscopy are the three cornerstones of classical structural biology. These technologies have helped provide fundamental and detailed knowledge regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the related human host proteins as well as enabled the identification of its target sites, facilitating the cessation of its transmission. Further progress into protein structure modeling was made using modern structure-based approaches derived from homology modeling and integrated with artificial intelligence (AI), facilitating advanced computational simulation tools to actively guide the design of new vaccines and the development of anti-SARS-CoV-2 drugs. This review presents the practical contributions and future directions of structure-based approaches for COVID-19.
引用
收藏
页码:139 / 141
页数:3
相关论文
共 50 条
  • [1] Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics
    Gupta, Yash
    Savytskyi, Oleksandr, V
    Coban, Matt
    Venugopal, Amoghavarsha
    Pleqi, Vasili
    Weber, Caleb A.
    Chitale, Rohit
    Durvasula, Ravi
    Hopkins, Christopher
    Kempaiah, Prakasha
    Caulfield, Thomas R.
    MOLECULAR ASPECTS OF MEDICINE, 2023, 91
  • [2] Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19
    Kaliamurthi, Satyavani
    Selvaraj, Gurudeeban
    Selvaraj, Chandrabose
    Singh, Sanjeev Kumar
    Wei, Dong-Qing
    Peslherbe, Gilles H.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (13)
  • [3] Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries
    Masoudi-Sobhanzadeh, Yosef
    Salemi, Aysan
    Pourseif, Mohammad M.
    Jafari, Behzad
    Omidi, Yadollah
    Masoudi-Nejad, Ali
    BRIEFINGS IN BIOINFORMATICS, 2021, 22 (06)
  • [4] Nanotechnology-based Approaches and Investigational Therapeutics against COVID-19
    Rahman, Md Mominur
    Ahmed, Muniruddin
    Islam, Mohammad Touhidul
    Khan, Md Robin
    Sultana, Sharifa
    Maeesa, Saila Kabir
    Hasan, Sakib
    Hossain, Md Abid
    Ferdous, Kazi Sayma
    Mathew, Bijo
    Rauf, Abdur
    Uddin, Md Sahab
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (12) : 948 - 968
  • [5] Structure-based approaches to drug discovery against tuberculosis
    Holton, Simon J.
    Weiss, Manfred S.
    Tucker, Paul A.
    Wilmanns, Matthias
    CURRENT PROTEIN & PEPTIDE SCIENCE, 2007, 8 (04) : 365 - 375
  • [6] COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
    Tripathi, Neetu
    Tripathi, Neeraj
    Goshisht, Manoj Kumar
    MOLECULAR DIVERSITY, 2022, 26 (01) : 629 - 645
  • [7] COVID-19: inflammatory responses, structure-based drug design and potential therapeutics
    Neetu Tripathi
    Neeraj Tripathi
    Manoj Kumar Goshisht
    Molecular Diversity, 2022, 26 : 629 - 645
  • [8] Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins
    Hijikata, Atsushi
    Shionyu, Clara
    Nakae, Setsu
    Shionyu, Masafumi
    Ota, Motonori
    Kanaya, Shigehiko
    Shirai, Tsuyoshi
    BIOPHYSICS AND PHYSICOBIOLOGY, 2021, 18 : 226 - 240
  • [9] Immune-mediated approaches against COVID-19
    Helena F. Florindo
    Ron Kleiner
    Daniella Vaskovich-Koubi
    Rita C. Acúrcio
    Barbara Carreira
    Eilam Yeini
    Galia Tiram
    Yulia Liubomirski
    Ronit Satchi-Fainaro
    Nature Nanotechnology, 2020, 15 : 630 - 645
  • [10] Immune-mediated approaches against COVID-19
    Florindo, Helena F.
    Kleiner, Ron
    Vaskovich-Koubi, Daniella
    Acurcio, Rita C.
    Carreira, Barbara
    Yeini, Eilam
    Tiram, Galia
    Liubomirski, Yulia
    Satchi-Fainaro, Ronit
    NATURE NANOTECHNOLOGY, 2020, 15 (08) : 630 - 645